Deals

Eli Lilly to Buy Loxo Oncology for $8 Billion

Eli Lilly to acquire approved cancer medine, plus pipeline
$235 per-share price is a 68% premium to Loxo’s Friday close

Eli Lilly is buying quiring Loxo Oncology for about $8 billion in cash. Bloomberg’s Rebecca Spalding reports.Source: Bloomberg)

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Rebecca Spalding

January 7, 2019 at 11:50 AM UTC

Updated on

January 7, 2019 at 2:53 PM UTC

This article is for subscribers only.

Eli Lilly & Co. will acquire Loxo Oncology Inc. for about $8 billion in cash, the second multibillion-dollar cancer deal of the year by a major U.S. pharmaceutical company.

The purchase is Indianapolis-based Lilly’s biggest takeover ever, according to data compiled by Bloomberg. Loxo holders will get $235 per share in cash, the companies said in a statement Monday. The Stamford, Connecticut-based biotechnology company is developing cancer treatments that target a tumor’s genetic markers regardless of where in the body they’re located.